The observed correlation between SREBP2 and some MVP genes, such as HMGCR, with tumor grade and worse survival in RMS patients suggests that synthetic targeting of SREBP2 and MVP could be an attractive option to improve the multimodal treatment. This evidence concerns the gene SREBF2 and neoplasm.